761 related articles for article (PubMed ID: 27627196)
21. The novel YAP target gene, SGK1, upregulates TAZ activity by blocking GSK3β-mediated TAZ destabilization.
Yoo G; Kim T; Chung C; Hwang DS; Lim DS
Biochem Biophys Res Commun; 2017 Aug; 490(3):650-656. PubMed ID: 28634071
[TBL] [Abstract][Full Text] [Related]
22. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ.
Zhang Z; Du J; Wang S; Shao L; Jin K; Li F; Wei B; Ding W; Fu P; van Dam H; Wang A; Jin J; Ding C; Yang B; Zheng M; Feng XH; Guan KL; Zhang L
Mol Cell; 2019 Jan; 73(1):7-21.e7. PubMed ID: 30472188
[TBL] [Abstract][Full Text] [Related]
23. The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications.
Maugeri-Saccà M; Barba M; Pizzuti L; Vici P; Di Lauro L; Dattilo R; Vitale I; Bartucci M; Mottolese M; De Maria R
Expert Rev Mol Med; 2015 Jul; 17():e14. PubMed ID: 26136233
[TBL] [Abstract][Full Text] [Related]
24. YAP/TAZ at the Roots of Cancer.
Zanconato F; Cordenonsi M; Piccolo S
Cancer Cell; 2016 Jun; 29(6):783-803. PubMed ID: 27300434
[TBL] [Abstract][Full Text] [Related]
25. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies.
Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
[TBL] [Abstract][Full Text] [Related]
26. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review.
Crawford JJ; Bronner SM; Zbieg JR
Expert Opin Ther Pat; 2018 Dec; 28(12):867-873. PubMed ID: 30482112
[No Abstract] [Full Text] [Related]
27. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
28. Hippo pathway-independent restriction of TAZ and YAP by angiomotin.
Chan SW; Lim CJ; Chong YF; Pobbati AV; Huang C; Hong W
J Biol Chem; 2011 Mar; 286(9):7018-26. PubMed ID: 21224387
[TBL] [Abstract][Full Text] [Related]
29. Hypoxic conditions differentially regulate TAZ and YAP in cancer cells.
Yan L; Cai Q; Xu Y
Arch Biochem Biophys; 2014 Nov; 562():31-6. PubMed ID: 25078107
[TBL] [Abstract][Full Text] [Related]
30. Knockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expression.
Guo L; Zheng J; Zhang J; Wang H; Shao G; Teng L
Oncol Rep; 2016 Aug; 36(2):729-36. PubMed ID: 27373987
[TBL] [Abstract][Full Text] [Related]
31. TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells.
Diamantopoulou Z; White G; Fadlullah MZH; Dreger M; Pickering K; Maltas J; Ashton G; MacLeod R; Baillie GS; Kouskoff V; Lacaud G; Murray GI; Sansom OJ; Hurlstone AFL; Malliri A
Cancer Cell; 2017 May; 31(5):621-634.e6. PubMed ID: 28416184
[TBL] [Abstract][Full Text] [Related]
32. Actin like-6A promotes glioma progression through stabilization of transcriptional regulators YAP/TAZ.
Ji J; Xu R; Zhang X; Han M; Xu Y; Wei Y; Ding K; Wang S; Bin Huang ; Chen A; Di Zhang ; Jiang Z; Xu S; Zhang Q; Li W; Ni S; Wang J; Li X
Cell Death Dis; 2018 May; 9(5):517. PubMed ID: 29725063
[TBL] [Abstract][Full Text] [Related]
33. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ.
Tan G; Cao X; Dai Q; Zhang B; Huang J; Xiong S; Zhang Yy; Chen W; Yang J; Li H
Oncotarget; 2015 Apr; 6(11):8676-86. PubMed ID: 25895125
[TBL] [Abstract][Full Text] [Related]
34. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
Kim MH; Kim J; Hong H; Lee SH; Lee JK; Jung E; Kim J
EMBO J; 2016 Mar; 35(5):462-78. PubMed ID: 26668268
[TBL] [Abstract][Full Text] [Related]
35. The Hippo pathway terminal effector TAZ/WWTR1 mediates oxaliplatin sensitivity in p53 proficient colon cancer cells.
Slaninová V; Heron-Milhavet L; Robin M; Jeanson L; Aissanou A; Kantar D; Tosi D; Bréhélin L; Gongora C; Djiane A
BMC Cancer; 2024 May; 24(1):587. PubMed ID: 38741073
[TBL] [Abstract][Full Text] [Related]
36. Flow-dependent YAP/TAZ activities regulate endothelial phenotypes and atherosclerosis.
Wang KC; Yeh YT; Nguyen P; Limqueco E; Lopez J; Thorossian S; Guan KL; Li YJ; Chien S
Proc Natl Acad Sci U S A; 2016 Oct; 113(41):11525-11530. PubMed ID: 27671657
[TBL] [Abstract][Full Text] [Related]
37. Substratum stiffness and latrunculin B modulate the gene expression of the mechanotransducers YAP and TAZ in human trabecular meshwork cells.
Thomasy SM; Morgan JT; Wood JA; Murphy CJ; Russell P
Exp Eye Res; 2013 Aug; 113():66-73. PubMed ID: 23727052
[TBL] [Abstract][Full Text] [Related]
38. Antitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cells.
Zhou X; Su J; Feng S; Wang L; Yin X; Yan J; Wang Z
Oncotarget; 2016 Nov; 7(48):79076-79088. PubMed ID: 27738325
[TBL] [Abstract][Full Text] [Related]
39. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
40. Arterial stiffness induces remodeling phenotypes in pulmonary artery smooth muscle cells via YAP/TAZ-mediated repression of cyclooxygenase-2.
Dieffenbach PB; Haeger CM; Coronata AMF; Choi KM; Varelas X; Tschumperlin DJ; Fredenburgh LE
Am J Physiol Lung Cell Mol Physiol; 2017 Sep; 313(3):L628-L647. PubMed ID: 28642262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
